Back to search

Article

ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer

2022-07-01

Abstract excerpt

<h4>Background: </h4> Pancreatic cancer is one of the most malignant tumors, with rapid metastasis, high mortality rate, and difficult early screening. Currently, gemcitabine is a first-line drug for pancreatic cancer patients, but its clinical effect is limited due to drug resistance. It is particularly important to further identify biomarkers associated with gemcitabine resistance to improve the sensitivity of g...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4c5ea2d3-8d99-5e67-8f42-ff1a3d36c0b7
DOI
10.21203/rs.3.rs-1797365/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancerDOI 10.21203/rs.3.rs-1797365/v1
Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity
A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patientsSemantic proximity
Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma.Semantic proximity
Pancreatic cancer organoids derived from EUS-guided fine needle aspiration specimens can be used to predict chemotherapy resistance.Semantic proximity
Combination of RUNX1 inhibitor and gemcitabine to mitigate chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2a-axis-mediated endoplasmic reticulum stressSemantic proximity
Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsSemantic proximity
Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal AdenocarcinomaSemantic proximity
RNA binding protein Pumilio2 promotes chemoresistance of pancreatic cancer via focal adhesion pathway and interacting with transcription factor EGR1Semantic proximity
Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugsSemantic proximity
Prognostic Significance of EIF4G1 in Patients with Pancreatic Ductal Adenocarcinoma<strong> </strong>Semantic proximity
E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGASemantic proximity
The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironmentSemantic proximity
Select a neighboring publication to make it the new centre.